ERBB2 and breast carcinoma: Similar intra-tumor heterogeneity has been reported in numerous cancers, including lung adenocarcinoma [40], meningioma [41], HER2-positive breast cancer [42], prostate cancer [43] pancreatic ductal adenocarcinoma [44], glioblastoma [45], colorectal cancer [46], liver cancer [47], lymphoma [48] and many others [49,50].